シンポジウム3：NMOSDに対する生物学的製剤治療の現状と課題
Rituximab・CD20抗体の現状と課題
2023 年 40 巻 3 号 p. 292-294
詳細
2023 年 40 巻 3 号 p. 292-294
Rituximab was approved on 20th June, 2022 based on the results of the RIN–1 study : a multicentre, randomised, double–blind, placebo–controlled trial for evaluating the safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (NMOSD). We discussed the current states and issues of rituximab use in patients with NMOSD.
